{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T19:40:54Z","timestamp":1794339654489,"version":"4.9.0"},"reference-count":102,"publisher":"Society for Neuroscience","issue":"46","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":181,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"funder":[{"name":"HHS | NIH | National Institute of Mental Health","award":["MH59911"],"award-info":[{"award-number":["MH59911"]}]},{"DOI":"10.13039\/100000062","name":"HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"crossref","award":["DK100685"],"award-info":[{"award-number":["DK100685"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"crossref"}]},{"name":"HHS | NIH | NIDDK | Division of Diabetes, Endocrinology, and Metabolic Diseases","award":["DK133465"],"award-info":[{"award-number":["DK133465"]}]},{"name":"HHS | NIH | NIDDK | Division of Diabetes, Endocrinology, and Metabolic Diseases","award":["DK112812"],"award-info":[{"award-number":["DK112812"]}]},{"name":"HHS | NIH | National Institute on Aging","award":["AG089445"],"award-info":[{"award-number":["AG089445"]}]},{"name":"HHS | NIH | National Institute on Minority Health and Health Disparities","award":["MD019614"],"award-info":[{"award-number":["MD019614"]}]}],"content-domain":{"domain":["jneurosci.org"],"crossmark-restriction":true},"short-container-title":["J. Neurosci."],"accepted":{"date-parts":[[2025,8,10]]},"published-print":{"date-parts":[[2025,11,12]]},"abstract":"<jats:p>Glucagon-like peptide-1 receptor (GLP-1R) agonists have revolutionized the therapeutic landscape of diabetes and obesity, yet their therapeutic potential extends significantly further. Research using human data and animal models indicates that systemically administered GLP-1R agonists access receptors in the periphery and in the brain. The latter site of action underlies the apparent efficacy of GLP-1R agonists to treat pathological consummatory behaviors that lead not only to obesity but also to binge-type eating disorders, alcohol use disorder, and other substance use disorders. This article provides an overview of basic science research, human clinical data, and real-world observations relevant to these topics and presented in a symposium at the 2025 Annual Meeting of the Society for Neuroscience.<\/jats:p>","DOI":"10.1523\/jneurosci.1375-25.2025","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T19:52:23Z","timestamp":1762977143000},"page":"e1375252025","update-policy":"https:\/\/doi.org\/10.1523\/jneurosci.crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["GLP-1 Receptor Agonists and Research to Treat Overeating and Substance Use Disorders"],"prefix":"10.1523","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9799-2592","authenticated-orcid":false,"given":"Jingchuan","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9782-6551","authenticated-orcid":false,"given":"Matthew R.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7284-8754","authenticated-orcid":false,"given":"Lorenzo","family":"Leggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1572-4506","authenticated-orcid":false,"given":"Ena","family":"Oru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5999-8811","authenticated-orcid":false,"given":"Linda","family":"Rinaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"393","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"2025111212300797000_45.46.e1375252025.1","doi-asserted-by":"crossref","first-page":"8056440","DOI":"10.1155\/2024\/8056440","article-title":"A comprehensive review on weight gain following discontinuation of glucagon-like peptide-1 receptor agonists for obesity","volume":"2024","author":"Abdullah Bin Ahmed","year":"2024","journal-title":"J Obes"},{"key":"2025111212300797000_45.46.e1375252025.2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2011-1443"},{"key":"2025111212300797000_45.46.e1375252025.3","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2014.74"},{"key":"2025111212300797000_45.46.e1375252025.4","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/osp4.619","article-title":"A pilot randomized controlled trial of liraglutide 3.0mg for binge eating disorder","volume":"9","author":"Allison","year":"2023","journal-title":"Obes Sci Pract"},{"key":"2025111212300797000_45.46.e1375252025.5","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association (2022) Diagnostic and statistical manual of mental disorders: DSM-5-TRTM, fifth edition, text revision. Washington, DC: American Psychiatric Association Publishing.","DOI":"10.1176\/appi.books.9780890425787"},{"key":"2025111212300797000_45.46.e1375252025.6","doi-asserted-by":"crossref","first-page":"108614","DOI":"10.1016\/j.drugalcdep.2021.108614","article-title":"Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder","volume":"221","author":"Angarita","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"2025111212300797000_45.46.e1375252025.7","first-page":"100333","article-title":"GLP-1 receptor agonists: a novel pharmacotherapy for binge eating (binge eating disorder and bulimia nervosa)? A systematic review","volume":"35","author":"Aoun","year":"2024","journal-title":"J Clin Transl Endocrinol"},{"key":"2025111212300797000_45.46.e1375252025.8","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3390\/brainsci14060617","article-title":"Exploring the potential impact of GLP-1 receptor agonists on substance use, compulsive behavior, and libido: insights from social media using a mixed-methods approach","volume":"14","author":"Arillotta","year":"2024","journal-title":"Brain Sci"},{"key":"2025111212300797000_45.46.e1375252025.9","doi-asserted-by":"crossref","first-page":"114622","DOI":"10.1016\/j.physbeh.2024.114622","article-title":"Glucagon-like peptide 1 agonist and effects on reward behaviour: a systematic review","volume":"283","author":"Badulescu","year":"2024","journal-title":"Physiol Behav"},{"key":"2025111212300797000_45.46.e1375252025.10","doi-asserted-by":"crossref","first-page":"e230405","DOI":"10.1530\/JOE-23-0405","article-title":"The emerging role of glucagon-like peptide 1 in binge eating","volume":"262","author":"Balantekin","year":"2024","journal-title":"J Endocrinol"},{"key":"2025111212300797000_45.46.e1375252025.11","doi-asserted-by":"publisher","DOI":"10.1080\/14622200210123581"},{"key":"2025111212300797000_45.46.e1375252025.12","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwn301"},{"key":"2025111212300797000_45.46.e1375252025.13","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12824"},{"key":"2025111212300797000_45.46.e1375252025.14","doi-asserted-by":"crossref","first-page":"ENEURO.0443-18.2019","DOI":"10.1523\/ENEURO.0443-18.2019","article-title":"Glucagon-like peptide-1 receptor agonist treatment does not reduce abuse-related effects of opioid drugs","volume":"6","author":"Bornebusch","year":"2019","journal-title":"eNeuro"},{"key":"2025111212300797000_45.46.e1375252025.15","first-page":"5","article-title":"Social media as pharmacovigilance: the potential for patient reports to inform clinical research on glucagon-like peptide 1 (GLP-1) receptor agonists for substance use disorders","volume":"85","author":"Bremmer","year":"2024","journal-title":"J Stud Alcohol Drugs"},{"key":"2025111212300797000_45.46.e1375252025.16","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s42255-021-00344-4","article-title":"Central and peripheral GLP-1 systems independently suppress eating","volume":"3","author":"Brierley","year":"2021","journal-title":"Nat Metab"},{"key":"2025111212300797000_45.46.e1375252025.17","doi-asserted-by":"crossref","first-page":"107312","DOI":"10.1016\/j.phrs.2024.107312","article-title":"IUPHAR review \u2013 glucagon-like peptide-1 (GLP-1) and substance use disorders: an emerging pharmacotherapeutic target","volume":"207","author":"Bruns Vi","year":"2024","journal-title":"Pharmacol Res"},{"key":"2025111212300797000_45.46.e1375252025.18","doi-asserted-by":"publisher","DOI":"10.1016\/J.DIABET.2019.101117"},{"key":"2025111212300797000_45.46.e1375252025.19","doi-asserted-by":"crossref","first-page":"e12340","DOI":"10.1111\/cob.12340","article-title":"Changes in health-related quality of life with intensive behavioural therapy combined with liraglutide 3.0mg per day","volume":"9","author":"Chao","year":"2019","journal-title":"Clin Obes"},{"key":"2025111212300797000_45.46.e1375252025.20","doi-asserted-by":"publisher","DOI":"10.2337\/dbi18-0045"},{"key":"2025111212300797000_45.46.e1375252025.21","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.dsx.2020.03.009","article-title":"Dulaglutide reduces binge episodes in type 2 diabetic patients with binge eating disorder: a pilot study","volume":"14","author":"Da Porto","year":"2020","journal-title":"Diabetes Metab Syndr"},{"key":"2025111212300797000_45.46.e1375252025.22","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fendo.2019.00080","article-title":"Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes","volume":"10","author":"Deacon","year":"2019","journal-title":"Front Endocrinol"},{"key":"2025111212300797000_45.46.e1375252025.23","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-023-06367-x"},{"key":"2025111212300797000_45.46.e1375252025.24","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.6326-11.2012"},{"key":"2025111212300797000_45.46.e1375252025.25","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3262-11.2011"},{"key":"2025111212300797000_45.46.e1375252025.26","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-0599"},{"key":"2025111212300797000_45.46.e1375252025.27","doi-asserted-by":"crossref","first-page":"105684","DOI":"10.1016\/j.ebiom.2025.105684","article-title":"An inhibitory GLP-1 circuit in the lateral septum modulates reward processing and alcohol intake in rodents","volume":"115","author":"Edvardsson","year":"2025","journal-title":"EBioMedicine"},{"key":"2025111212300797000_45.46.e1375252025.28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0069010"},{"key":"2025111212300797000_45.46.e1375252025.29","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2020.614884"},{"key":"2025111212300797000_45.46.e1375252025.30","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00429-020-02189-1","article-title":"Distribution and ultrastructural localization of the glucagon-like peptide-1 receptor (GLP-1R) in the rat brain","volume":"226","author":"Farkas","year":"2021","journal-title":"Brain Struct Funct"},{"key":"2025111212300797000_45.46.e1375252025.31","doi-asserted-by":"crossref","first-page":"e188314","DOI":"10.1172\/JCI188314","article-title":"Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake","volume":"135","author":"Farokhnia","year":"2025","journal-title":"J Clin Invest"},{"key":"2025111212300797000_45.46.e1375252025.32","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.28.5.w822"},{"key":"2025111212300797000_45.46.e1375252025.33","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/oby.2009.253","article-title":"Individual and aggregate years-of-life-lost associated with overweight and obesity","volume":"18","author":"Finkelstein","year":"2010","journal-title":"Obesity"},{"key":"2025111212300797000_45.46.e1375252025.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2017.03.019"},{"key":"2025111212300797000_45.46.e1375252025.35","doi-asserted-by":"crossref","unstructured":"Freet CS , et al. (2025) Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with treatment-refractory OUD: a randomized, double-blind, placebo-controlled clinical trial protocol. Available at: https:\/\/www.researchsquare.com\/article\/rs-6666196\/v1 [Accessed July 16, 2025].","DOI":"10.21203\/rs.3.rs-6666196\/v1"},{"key":"2025111212300797000_45.46.e1375252025.36","doi-asserted-by":"crossref","first-page":"e133429","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI Insight"},{"key":"2025111212300797000_45.46.e1375252025.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2012.06.015"},{"key":"2025111212300797000_45.46.e1375252025.38","doi-asserted-by":"publisher","DOI":"10.1002\/cne.23282"},{"key":"2025111212300797000_45.46.e1375252025.39","doi-asserted-by":"publisher","DOI":"10.1210\/en.2008-1479"},{"key":"2025111212300797000_45.46.e1375252025.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2011.02.001"},{"key":"2025111212300797000_45.46.e1375252025.41","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-nutr-071812-161201"},{"key":"2025111212300797000_45.46.e1375252025.42","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cobeha.2016.02.005","article-title":"GLP-1 influences food and drug reward","volume":"9","author":"Hayes","year":"2016","journal-title":"Curr Opin Behav Sci"},{"key":"2025111212300797000_45.46.e1375252025.43","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial","volume":"82","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"2025111212300797000_45.46.e1375252025.44","doi-asserted-by":"crossref","first-page":"114565","DOI":"10.1016\/j.physbeh.2024.114565","article-title":"Targeting GLP-1 receptors to reduce nicotine use disorder: preclinical and clinical evidence","volume":"281","author":"Herman","year":"2024","journal-title":"Physiol Behav"},{"key":"2025111212300797000_45.46.e1375252025.45","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.physbeh.2019.03.026","article-title":"Central GLP-1 receptors: novel molecular targets for cocaine use disorder","volume":"206","author":"Hernandez","year":"2019","journal-title":"Physiol Behav"},{"key":"2025111212300797000_45.46.e1375252025.46","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.53.suppl_3.S197"},{"key":"2025111212300797000_45.46.e1375252025.47","doi-asserted-by":"publisher","DOI":"10.2337\/db18-0729"},{"key":"2025111212300797000_45.46.e1375252025.48","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2014.175"},{"key":"2025111212300797000_45.46.e1375252025.49","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07685-6"},{"key":"2025111212300797000_45.46.e1375252025.50","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/ajhp\/zxaf088","article-title":"Dulaglutide use to improve binge eating behaviors in a person with type 2 diabetes and obesity","volume":"82","author":"Innocent","year":"2025","journal-title":"Am J Health Syst Pharm"},{"key":"2025111212300797000_45.46.e1375252025.51","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/acer.70041","article-title":"Blood phosphatidylethanol measurements indicate GLP-1 receptor stimulation causes delayed decreases in alcohol consumption","volume":"49","author":"Jensen","year":"2025","journal-title":"Alcohol Clin Exp Res"},{"key":"2025111212300797000_45.46.e1375252025.52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2018.11.005","article-title":"Gut-brain axis and addictive disorders: a review with focus on alcohol and drugs of abuse","volume":"196","author":"Jerlhag","year":"2019","journal-title":"Pharmacol Ther"},{"key":"2025111212300797000_45.46.e1375252025.53","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.3390\/jcm14093122","article-title":"Glucagon-like peptide-1 receptor agonists in the context of eating disorders: a promising therapeutic option or a double-edged sword?","volume":"14","author":"Ka\u0142as","year":"2025","journal-title":"J Clin Med"},{"key":"2025111212300797000_45.46.e1375252025.54","doi-asserted-by":"crossref","first-page":"e159863","DOI":"10.1172\/jci.insight.159863","article-title":"Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial","volume":"7","author":"Klausen","year":"2022","journal-title":"JCI Insight"},{"key":"2025111212300797000_45.46.e1375252025.55","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/jamapsychiatry.2024.3599","article-title":"Repurposing semaglutide and liraglutide for alcohol use disorder","volume":"82","author":"L\u00e4hteenvuo","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"2025111212300797000_45.46.e1375252025.56","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02634-8"},{"key":"2025111212300797000_45.46.e1375252025.57","doi-asserted-by":"crossref","first-page":"101865","DOI":"10.1016\/j.eclinm.2023.101865","article-title":"Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial","volume":"57","author":"Lengsfeld","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2025111212300797000_45.46.e1375252025.58","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2017.187"},{"key":"2025111212300797000_45.46.e1375252025.59","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.molmet.2018.11.005","article-title":"GLP-1 modulates the supramammillary nucleus-lateral hypothalamic neurocircuit to control ingestive and motivated behavior in a sex divergent manner","volume":"20","author":"L\u00f3pez-Ferreras","year":"2019","journal-title":"Mol Metab"},{"key":"2025111212300797000_45.46.e1375252025.60","doi-asserted-by":"crossref","unstructured":"Merkel R , Hernandez N , Weir V , Zhang Y , Rich MT , Crist RC , Reiner BC , Schmidt HD (2024) An endogenous GLP-1 circuit engages VTA GABA neurons to regulate mesolimbic dopamine neurons and attenuate cocaine seeking. Available at: http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2024.06.20.599574 [Accessed October 20, 2024].","DOI":"10.1101\/2024.06.20.599574"},{"key":"2025111212300797000_45.46.e1375252025.61","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00413.2013"},{"key":"2025111212300797000_45.46.e1375252025.62","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0115-14.2014"},{"key":"2025111212300797000_45.46.e1375252025.63","doi-asserted-by":"crossref","first-page":"113869","DOI":"10.1016\/j.bbr.2022.113869","article-title":"The impact of binge-like palatable food intake on the endogenous glucagon-like peptide-1 system in female rats","volume":"428","author":"Mukherjee","year":"2022","journal-title":"Behav Brain Res"},{"key":"2025111212300797000_45.46.e1375252025.64","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O\u2019Neil","year":"2018","journal-title":"Lancet"},{"key":"2025111212300797000_45.46.e1375252025.65","doi-asserted-by":"publisher","DOI":"10.2337\/diab.45.6.832"},{"key":"2025111212300797000_45.46.e1375252025.66","doi-asserted-by":"crossref","first-page":"e192414","DOI":"10.1172\/JCI192414","article-title":"GLP-1 receptor agonists for the treatment of alcohol use disorder","volume":"135","author":"Petrie","year":"2025","journal-title":"J Clin Invest"},{"key":"2025111212300797000_45.46.e1375252025.67","doi-asserted-by":"crossref","first-page":"e170419","DOI":"10.1172\/jci.insight.170419","article-title":"Effects of dulaglutide on alcohol consumption during smoking cessation","volume":"8","author":"Probst","year":"2023","journal-title":"JCI Insight"},{"key":"2025111212300797000_45.46.e1375252025.68","doi-asserted-by":"publisher","DOI":"10.1210\/en.2013-1934"},{"key":"2025111212300797000_45.46.e1375252025.69","doi-asserted-by":"publisher","DOI":"10.1111\/add.16679"},{"key":"2025111212300797000_45.46.e1375252025.70","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-48267-2"},{"key":"2025111212300797000_45.46.e1375252025.71","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2063-23.2024"},{"key":"2025111212300797000_45.46.e1375252025.72","doi-asserted-by":"publisher","DOI":"10.1210\/en.2014-1248"},{"key":"2025111212300797000_45.46.e1375252025.73","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0119034"},{"key":"2025111212300797000_45.46.e1375252025.74","doi-asserted-by":"crossref","first-page":"100080","DOI":"10.1016\/j.obpill.2023.100080","article-title":"Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: a retrospective cohort study","volume":"7","author":"Richards","year":"2023","journal-title":"Obes Pillars"},{"key":"2025111212300797000_45.46.e1375252025.75","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.orcp.2015.03.005","article-title":"Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide \u2013 a pilot study","volume":"9","author":"Robert","year":"2015","journal-title":"Obes Res Clin Pract"},{"key":"2025111212300797000_45.46.e1375252025.76","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13256-025-05049-w","article-title":"Use of semaglutide in a 54-year-old patient with cocaine abuse and weight loss: a case report","volume":"19","author":"Romeo","year":"2025","journal-title":"J Med Case Rep"},{"key":"2025111212300797000_45.46.e1375252025.77","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2013.47"},{"key":"2025111212300797000_45.46.e1375252025.78","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00479.2002"},{"key":"2025111212300797000_45.46.e1375252025.79","doi-asserted-by":"publisher","DOI":"10.1172\/JCI75276"},{"key":"2025111212300797000_45.46.e1375252025.80","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061965"},{"key":"2025111212300797000_45.46.e1375252025.81","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2147\/DMSO.S141235","article-title":"Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes","volume":"10","author":"Sikirica","year":"2017","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2025111212300797000_45.46.e1375252025.82","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2013.00181"},{"key":"2025111212300797000_45.46.e1375252025.83","doi-asserted-by":"publisher","DOI":"10.1177\/2042018815580257"},{"key":"2025111212300797000_45.46.e1375252025.84","doi-asserted-by":"crossref","first-page":"15542","DOI":"10.1038\/s41598-019-51880-9","article-title":"A unique olfactory bulb microcircuit driven by neurons expressing the precursor to glucagon-like peptide 1","volume":"9","author":"Thiebaud","year":"2019","journal-title":"Sci Rep"},{"key":"2025111212300797000_45.46.e1375252025.85","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15638"},{"key":"2025111212300797000_45.46.e1375252025.86","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00333.2015"},{"key":"2025111212300797000_45.46.e1375252025.87","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/jcpt.13225","article-title":"Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes","volume":"45","author":"Trujillo","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"2025111212300797000_45.46.e1375252025.88","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200404000-00020"},{"key":"2025111212300797000_45.46.e1375252025.89","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/oby.22359","article-title":"Intensive behavioral therapy for obesity combined with liraglutide 3.0mg: a randomized controlled trial","volume":"27","author":"Wadden","year":"2019","journal-title":"Obesity"},{"key":"2025111212300797000_45.46.e1375252025.90","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48780-6"},{"key":"2025111212300797000_45.46.e1375252025.91","doi-asserted-by":"publisher","DOI":"10.7326\/M23-2718"},{"key":"2025111212300797000_45.46.e1375252025.92","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-024-02498-5"},{"key":"2025111212300797000_45.46.e1375252025.93","doi-asserted-by":"crossref","first-page":"e2435247","DOI":"10.1001\/jamanetworkopen.2024.35247","article-title":"Semaglutide and opioid overdose risk in patients with type 2 diabetes and opioid use disorder","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2025111212300797000_45.46.e1375252025.94","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/bcpt.13776","article-title":"Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events. A nationwide register-based cohort and self-controlled case series study","volume":"131","author":"Wium-Andersen","year":"2022","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2025111212300797000_45.46.e1375252025.95","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1186\/s12916-025-04200-0","article-title":"Trajectory of the body weight after drug discontinuation in the treatment of anti-obesity medications","volume":"23","author":"Wu","year":"2025","journal-title":"BMC Med"},{"key":"2025111212300797000_45.46.e1375252025.96","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/978-88-470-5322-9_140","article-title":"Biological state marker for alcohol consumption","volume-title":"Textbook of addiction treatment: international perspectives","volume":"Chapter 140","author":"Wurst","year":"2015"},{"key":"2025111212300797000_45.46.e1375252025.97","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03412-w"},{"key":"2025111212300797000_45.46.e1375252025.98","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/ntr\/ntab066","article-title":"Exenatide adjunct to nicotine patch facilitates smoking cessation and may reduce post-cessation weight gain: a pilot randomized controlled trial","volume":"23","author":"Yammine","year":"2021","journal-title":"Nicotine Tob Res"},{"key":"2025111212300797000_45.46.e1375252025.99","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/ADM.0000000000001147","article-title":"Feasibility of exenatide, a GLP-1R agonist, for treating cocaine use disorder: a case series study","volume":"17","author":"Yammine","year":"2023","journal-title":"J Addict Med"},{"key":"2025111212300797000_45.46.e1375252025.100","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/ntr\/ntaf005","article-title":"Exploring predictors of treatment response to GLP-1 receptor agonists for smoking cessation","volume":"27","author":"Yammine","year":"2025","journal-title":"Nicotine Tob Res"},{"key":"2025111212300797000_45.46.e1375252025.101","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-019-0531-4"},{"key":"2025111212300797000_45.46.e1375252025.102","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Sig Transduct Target Ther"}],"container-title":["The Journal of Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1523\/JNEUROSCI.1375-25.2025","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1523\/JNEUROSCI.1375-25.2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T02:08:49Z","timestamp":1762999729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jneurosci.org\/lookup\/doi\/10.1523\/JNEUROSCI.1375-25.2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":102,"journal-issue":{"issue":"46","published-online":{"date-parts":[[2025,11,12]]},"published-print":{"date-parts":[[2025,11,12]]}},"alternative-id":["10.1523\/JNEUROSCI.1375-25.2025"],"URL":"https:\/\/doi.org\/10.1523\/jneurosci.1375-25.2025","relation":{},"ISSN":["0270-6474","1529-2401"],"issn-type":[{"value":"0270-6474","type":"print"},{"value":"1529-2401","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]}}}